NeoGenomics (NEO) reported $164.5 million in revenue for the quarter ended June 2024, representing a yearover-year increase of 12%. EPS of $0.03 for the same period compares to -$0.05 a year ago. ...

20 | --- | --- | --- | |--------------------------------------------------|---------|---------| | Balance Sheet In $Millions | Dec-23 | Jun-24 | | Cash and cash equivalents | 342.5 | 355.1 | | Marketable securities, at fair value | 72.7 | 32.8 | | Accounts receivable, net | 131.2 | 146.6 | | Inventories | 24.2 | 23.2 | | Prepaid assets | 18.0 | 17.4 | | Other current assets | 8.2 | 9.2 | | Total current assets | 596.8 | 584.2 | | Property and equipment, net | 92.0 | 92.2 | | Operating lease right-of-use ass ...

Exhibit 99.1 Fort Myers, Florida (July 29, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second-Quarter Results Net loss for the quarter decreased $6 million, or 23%, to $19 million compared to net loss of $24 million for the second quarter of 2023. Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 t ...

TORONTO, July 26, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) NEO and Lotus intend to develop a silicon anode product to co-market directly to battery cell, electronics, and automotive manufacturers. Both companies will explore joint venture opportunities to establish a North American footprint in silicon recycling. Governmental funding for international cooperation will be applied for in advanced manufacturing and clean technology based on availability and criteria-match. Headquartered in Melbourne, ...

FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1 marker. Trial expands from patients afflicted with Recurrent Grade IV Astrocytoma with IDH1 mutation to those with equally aggressive Recurrent Grade III Astrocytoma with IDH1 mutation. Enrollment in three other NeOnc clinical studies also advance after several published studies indicate the viability of NeOnc's NEO™ plat ...

Proactive has always been a forward looking and enthusiastic technology adopter. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. About this content Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company I ...

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) Collaboration Agreement with INNOX eco-M – Leading South Korean Chemical Material Company of Recycled Silicon Powders Subsidiary of INNOX Holding Corp. – A Producer of Secondary Battery Materials and IT HighTech Materials with Investment Business Operations Jointly Developing Silicon Anode Products with INNOX eco-M's High-Purity Recycled Silicon Development Priorities: Enhance Electrochemical Performance, Lower Anode Manufacturing Costs & E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - Chief Commercial Officer Melody Harris - Chief Operations Officer and President, Informatics Ali Olivo - EVP, General Counsel and Business Development Conference Call Participants Mark Massaro - BTIG Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Andrew Brackman - William Blair Tejas Savant - Morgan Stanley Mike M ...

For the quarter ended March 2024, NeoGenomics (NEO) reported revenue of $156.24 million, up 13.9% over the same period last year. EPS came in at -$0.02, compared to -$0.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $149.82 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.03.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...